Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Published: October 2011
The analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at a CAGR of 3.16 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rising diagnosis and treatment rates. The Global MS Therapeutics market has also been witnessing the emergence of biomarkers. However, the lack of therapies available to manage the progression of the disease could pose a challenge to the growth of this market.
The report, the Global Multiple Sclerosis (MS) Therapeutics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global MS Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this space include Bayer HealthCare AG, Biogen Idec Inc., Merck Serono SA, Novartis AG, and Teva Pharmaceutical Industries Ltd.
The other vendors mentioned in this report are AB Science, Abbvie Inc., Active Biotech AB, Astra Zeneca plc, Glaxo Smith Kline plc, Glenmark Pharmaceuticals Ltd., Hoffmann-La Roche Inc., and Sanofi SA.
Key questions answered in this report:
- What will the market size be in 2016 and what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
04. Market Research Methodology
Market Research Process
05. Scope of the Report
06. Market Landscape
06.1 Global MS Market
Market Size and Forecast
06.2 MS Market in the US
Market Size and Forecast
06.3 MS Market in Europe
Market Size and Forecast
06.4 Five Forces Analysis
07. Geographical Segmentation
08. Rate of Incidence and Prevalence
09. Vendor Landscape
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
15.1 Bayer HealthCare AG
15.2 Biogen Idec Inc.
15.3 Merck Serono SA
15.4 Novartis AG
15.5 Teva Pharmaceutical Industries Ltd.
16. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global MS Market 2012-2016 (US$ billion)
Exhibit 3: MS Market in the US 2012-2016 (US$ billion)
Exhibit 4: MS Market in Europe 2012-2016 (US$ billion)
Exhibit 5: Global MS Market by Geographical Segmentation 2012
Exhibit 6: Global MS Market by Vendor Segmentation 2012
Exhibit 7: Business Segmentation of Bayer HealthCare AG
Exhibit 8: Business Segmentation of Merck Serono SA
Exhibit 10: Business Segmentation of Novartis AG
Exhibit 12: Business Segmentation of Teva Pharmaceuticals Industries Ltd.
Commenting on the report, an analyst from the team said: “Currently, there is an increase in the adoption of biomarkers that are 100 percent specific to RRMS conditions. The use of biomarkers proves to be a sensitive indicator of the slightest disease activity in MS patients. A highly specific protein biomarker for MS aids in quick and precise identification of patients with the disease, possibly before clinically relevant symptoms arise. Thus, the use of biomarkers helps prevent the significant neurodegeneration associated with the disease. Recently, the Global MS market has witnessed various collaborations for MS biomarkers. Regulus Therapeutics and Biogen Idec entered into a collaboration to identify blood-based microRNAs as biomarkers for MS. It is believed by both partners that microRNA biomarkers aid in the selection of ideal patient segments in clinical trials and also in monitoring disease progression or relapse.”
According to the report, one of the main drivers is the increase in the diagnosis and treatment of MS. This is because of the usage of the latest revised McDonald diagnostic criteria in the treatment of MS. The McDonald diagnostic criteria consist of a combination of clinical, imaging, and paraclinical tests used in the diagnosis of MS. This latest revision has helped in improving the detection of the symptoms of the disease. A McDonald diagnostic criterion helps improve the sensitivity from around 46 percent to 74 percent. This indirectly aids in diagnosing MS more rapidly than in the early days.
Further, the report states that one of the major challenges in the market is the lack of therapies for the management of the progressive form of the disease. The patients under this category take only symptomatic treatment to improve their quality of life.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are AB Science, Abbvie Inc., Active Biotech AB, AstraZeneca plc, Genzyme, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Hoffmann-La Roche Inc., and Sanofi S.A.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- AB Science
- Abbvie Inc.
- Active Biotech AB
- Astra Zeneca plc
- Bayer HealthCare AG
- Biogen Idec Inc.
- Glaxo Smith Kline plc
- Glenmark Pharmaceuticals Ltd.
- Hoffmann-La Roche Inc.
- Merck Serono SA
- Novartis AG
- Sanofi SA.
- Teva Pharmaceutical Industries Ltd.